£52.0M
Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joined the financing round to support accelerated development of the company pipeline.
EyeBio
EyeBio develops a pipeline of novel therapies for retinal and eye diseases.
£52.0MTotal raised
EyeBio is a clinical stage ophthalmology biotechnology company developing therapies for sight threatening eye diseases. The firm operates across the United States and the United Kingdom.
Categories
Founders
DG
David Guyer
Chief Executive Officer and Co-Founder
TA
Tony Adamis
Chief Scientific Officer and Co-Founder